Kathryn Hughes Barry1, Lee E Moore1, Linda M Liao2, Wen-Yi Huang1, Gabriella Andreotti1, Matthew Poulin3, Sonja I Berndt1. 1. Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland. 2. Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland. 3. EpigenDx, Inc., Hopkinton, Massachusetts.
Abstract
BACKGROUND: Evidence suggests that global blood DNA methylation levels may be associated with the risk of various cancers, but no studies have evaluated this relationship for prostate cancer. METHODS: We used pyrosequencing to quantify DNA methylation levels at the long interspersed nuclear element 1 (LINE-1) and Alu repetitive elements in pre-diagnostic blood samples from 694 prostate cancer cases and 703 controls from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. We evaluated prostate cancer risk associated with the mean methylation level for each element using logistic regression, adjusting for potential confounders. RESULTS: We did not observe a significant association with prostate cancer for LINE-1 [odds ratio (OR) for the highest compared to the lowest quartile = 1.01, 95% confidence interval (CI): 0.73-1.39, Ptrend = 0.99] or Alu (OR = 0.94, 95% CI: 0.68-1.29, Ptrend = 0.69) methylation levels overall. However, for Alu, we observed that higher DNA methylation levels were associated with a significant increased risk for those diagnosed 4 or more years after blood draw (OR = 2.26, 95% CI: 1.27-4.00, Ptrend = 4.4 × 10(-3) ). In contrast, there was no association for those diagnosed 2 (OR = 1.13, 95% CI: 0.67-1.90, Ptrend = 0.64) or 3 years after draw (OR = 1.22, 95% CI: 0.71-2.07, Ptrend = 0.32), and a decreased risk for those diagnosed less than 2 years after draw (OR = 0.40, 95% CI: 0.25-0.65, Ptrend = 3.8 × 10(-5) ; Pheterogeneity = 5.3 × 10(-6) ). CONCLUSIONS: Although LINE-1 DNA methylation levels were not associated with prostate cancer, we observed an association for Alu that varied by time from blood draw to diagnosis. Our study suggests that elevated Alu blood DNA methylation levels several years before diagnosis may be associated with an increased prostate cancer risk.
RCT Entities:
BACKGROUND: Evidence suggests that global blood DNA methylation levels may be associated with the risk of various cancers, but no studies have evaluated this relationship for prostate cancer. METHODS: We used pyrosequencing to quantify DNA methylation levels at the long interspersed nuclear element 1 (LINE-1) and Alu repetitive elements in pre-diagnostic blood samples from 694 prostate cancer cases and 703 controls from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. We evaluated prostate cancer risk associated with the mean methylation level for each element using logistic regression, adjusting for potential confounders. RESULTS: We did not observe a significant association with prostate cancer for LINE-1 [odds ratio (OR) for the highest compared to the lowest quartile = 1.01, 95% confidence interval (CI): 0.73-1.39, Ptrend = 0.99] or Alu (OR = 0.94, 95% CI: 0.68-1.29, Ptrend = 0.69) methylation levels overall. However, for Alu, we observed that higher DNA methylation levels were associated with a significant increased risk for those diagnosed 4 or more years after blood draw (OR = 2.26, 95% CI: 1.27-4.00, Ptrend = 4.4 × 10(-3) ). In contrast, there was no association for those diagnosed 2 (OR = 1.13, 95% CI: 0.67-1.90, Ptrend = 0.64) or 3 years after draw (OR = 1.22, 95% CI: 0.71-2.07, Ptrend = 0.32), and a decreased risk for those diagnosed less than 2 years after draw (OR = 0.40, 95% CI: 0.25-0.65, Ptrend = 3.8 × 10(-5) ; Pheterogeneity = 5.3 × 10(-6) ). CONCLUSIONS: Although LINE-1 DNA methylation levels were not associated with prostate cancer, we observed an association for Alu that varied by time from blood draw to diagnosis. Our study suggests that elevated Alu blood DNA methylation levels several years before diagnosis may be associated with an increased prostate cancer risk.
Authors: Charlotte S Wilhelm; Karl T Kelsey; Rondi Butler; Silvia Plaza; Luc Gagne; M Scot Zens; Angeline S Andrew; Steven Morris; Heather H Nelson; Alan R Schned; Margaret R Karagas; Carmen J Marsit Journal: Clin Cancer Res Date: 2010-02-23 Impact factor: 12.531
Authors: Zhong-Zheng Zhu; David Sparrow; Lifang Hou; Letizia Tarantini; Valentina Bollati; Augusto A Litonjua; Antonella Zanobetti; Pantel Vokonas; Robert O Wright; Andrea Baccarelli; Joel Schwartz Journal: Cancer Causes Control Date: 2010-12-25 Impact factor: 2.506
Authors: Debra Ting Hsiung; Carmen J Marsit; E Andres Houseman; Karen Eddy; C Sloane Furniss; Michael D McClean; Karl T Kelsey Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-01 Impact factor: 4.254
Authors: Meredith Yeager; Nick Orr; Richard B Hayes; Kevin B Jacobs; Peter Kraft; Sholom Wacholder; Mark J Minichiello; Paul Fearnhead; Kai Yu; Nilanjan Chatterjee; Zhaoming Wang; Robert Welch; Brian J Staats; Eugenia E Calle; Heather Spencer Feigelson; Michael J Thun; Carmen Rodriguez; Demetrius Albanes; Jarmo Virtamo; Stephanie Weinstein; Fredrick R Schumacher; Edward Giovannucci; Walter C Willett; Geraldine Cancel-Tassin; Olivier Cussenot; Antoine Valeri; Gerald L Andriole; Edward P Gelmann; Margaret Tucker; Daniela S Gerhard; Joseph F Fraumeni; Robert Hoover; David J Hunter; Stephen J Chanock; Gilles Thomas Journal: Nat Genet Date: 2007-04-01 Impact factor: 38.330
Authors: Srinivasan Yegnasubramanian; Michael C Haffner; Yonggang Zhang; Bora Gurel; Toby C Cornish; Zhijin Wu; Rafael A Irizarry; James Morgan; Jessica Hicks; Theodore L DeWeese; William B Isaacs; G Steven Bova; Angelo M De Marzo; William G Nelson Journal: Cancer Res Date: 2008-11-01 Impact factor: 12.701
Authors: Ji-Yeob Choi; Smitha R James; Petra A Link; Susan E McCann; Chi-Chen Hong; Warren Davis; Mary K Nesline; Christine B Ambrosone; Adam R Karpf Journal: Carcinogenesis Date: 2009-07-07 Impact factor: 4.944
Authors: Vasanthi R Sunil; Kinal N Vayas; Mingzhu Fang; Helmut Zarbl; Christopher Massa; Andrew J Gow; Jessica A Cervelli; Howard Kipen; Robert J Laumbach; Paul J Lioy; Jeffrey D Laskin; Debra L Laskin Journal: Exp Mol Pathol Date: 2016-12-13 Impact factor: 3.362
Authors: Brian T Joyce; Tao Gao; Yinan Zheng; Lei Liu; Wei Zhang; Qi Dai; Martha J Shrubsole; Elizabeth A Hibler; Massimo Cristofanilli; Hu Zhang; Hushan Yang; Pantel Vokonas; Laura Cantone; Joel Schwartz; Andrea Baccarelli; Lifang Hou Journal: Br J Cancer Date: 2016-06-28 Impact factor: 7.640